Vaccination against hepatitis B virus (HBV) is a valuable tool in efforts to reduce transmission and meet U.S. viral hepatitis elimination goals. This project aims to examine the cost-effectiveness of a 2-dose vs 3-dose vaccine in various settings that serve persons considered to be at high risk for HBV infection.